Polytechnic University of Turin-ko ikertzaileekin lankidetzan egindako argitalpenak (16)

2022

  1. Ischemic-hemorrhagic balance in diabetic and non-diabetic patients after acute coronary syndrome

    REC: CardioClinics, Vol. 57, Núm. 3, pp. 203-211

2021

  1. Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets

    The Lancet, Vol. 397, Núm. 10270, pp. 199-207

  2. Ticagrelor or Clopidogrel After an Acute Coronary Syndrome in the Elderly: A Propensity Score Matching Analysis from 16,653 Patients Treated with PCI Included in Two Large Multinational Registries

    Cardiovascular Drugs and Therapy, Vol. 35, Núm. 6, pp. 1171-1182

  3. Ticagrelor versus prasugrel in acute coronary syndrome: sex-specific analysis from the RENAMI Registry

    Minerva cardiology and angiology, Vol. 69, Núm. 4, pp. 408-416

2020

  1. Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: Insights from the BleeMACS and RENAMI registries

    American Heart Journal, Vol. 220, pp. 108-115

  2. Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor

    International Journal of Cardiology, Vol. 301, pp. 200-206

  3. Efficacy and Safety of Clopidogrel, Prasugrel and Ticagrelor in ACS Patients Treated with PCI: A Propensity Score Analysis of the RENAMI and BleeMACS Registries

    American Journal of Cardiovascular Drugs, Vol. 20, Núm. 3, pp. 259-269

  4. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry

    European Journal of Preventive Cardiology, Vol. 27, Núm. 7, pp. 696-705

  5. P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects

    European heart journal. Cardiovascular pharmacotherapy, Vol. 6, Núm. 1, pp. 31-42

2019

  1. Annual Incidence of Confirmed Stent Thrombosis and Clinical Predictors in Patients With ACS Treated With Ticagrelor or Prasugrel

    Revista Espanola de Cardiologia, Vol. 72, Núm. 4, pp. 298-304

  2. Correction to: Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI Registry (American Journal of Cardiovascular Drugs, (2019), 19, 4, (381-391), 10.1007/s40256-019-00339-3)

    American Journal of Cardiovascular Drugs

  3. Prasugrel or ticagrelor in patients with acute coronary syndrome and diabetes: a propensity matched substudy of RENAMI

    European Heart Journal: Acute Cardiovascular Care, Vol. 8, Núm. 6, pp. 536-542

  4. Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI Registry

    American Journal of Cardiovascular Drugs, Vol. 19, Núm. 4, pp. 381-391

  5. Usefulness of the PARIS Score to Evaluate the Ischemic-hemorrhagic Net Benefit With Ticagrelor and Prasugrel After an Acute Coronary Syndrome

    Revista Espanola de Cardiologia, Vol. 72, Núm. 3, pp. 215-223

2018

  1. Anemia in patients with acute coronary syndromes treated with prasugrel or ticagrelor: Insights from the RENAMI registry

    Thrombosis Research, Vol. 167, pp. 142-148

  2. Incidence and predictors of bleeding in ACS patients treated with PCI and prasugrel or ticagrelor: An analysis from the RENAMI registry

    International Journal of Cardiology, Vol. 273, pp. 29-33